Ep. 676 - The Hidden Dangers of Leukoplakia: What Every Dentist Should Know

When you discover a white patch on your patient's tongue during routine treatment, do you know the critical difference between watching and acting? That clinical decision could literally be life-saving.

Dr. Ashley Clark joins us to share her expertise in oral pathology. She is an Associate Professor and Division Chief of Oral Pathology at the University of Kentucky College of Dentistry, holding a DDS from Indiana University and a certificate in Oral and Maxillofacial Pathology from The University of Florida. Dr. Clark has served on faculty at West Virginia University and University of Texas at Houston School of Dentistry, where she earned the John H. Freeman Award for Faculty Teaching and Dean's Excellence Award in the Scholarship of Teaching. She is a Fellow in the American College of Dentists, serves on the Commission on Dental Accreditation review board for oral and maxillofacial pathology programs, and sits on the Advisory Board for Oral Cancer Cause. With over 40 publications and more than 100 continuing education courses delivered, Dr. Clark currently serves as Vice President of CAMP Laboratory.

This episode delivers essential clinical guidance on recognizing, evaluating, and managing leukoplakia in general practice. Dr. Clark explains why every sharply demarcated white patch requires biopsy regardless of patient risk factors, and provides practical protocols for documentation, referral, and biopsy procedures that can be performed chairside.

Episode Highlights:

• Leukoplakia identification centers on sharply demarcated borders where you can clearly distinguish where the white patch ends and normal tissue begins, making this the primary diagnostic criterion rather than patient smoking or drinking history. High-risk locations include lateral tongue, ventral tongue, and floor of mouth, though gingival leukoplakia is increasingly common and often misdiagnosed as lichen planus.
• Every leukoplakia lesion requires biopsy without exception, as 85% of non-HPV oral cancers develop from preexisting white patches, and dysplasia can occur even in 13-year-old patients with no risk factors. The 80% benign rate for hyperkeratosis should not influence clinical decision-making, as the 20% dysplastic rate represents significant cancer risk.
• Patients without smoking or drinking histories actually warrant greater concern once leukoplakia develops, as they cannot modify behavioral risk factors and likely have genetic predisposition or P53 gene mutations driving the lesion development.
• Actinic cheilitis progresses predictably from border blurring to blotchy areas, scaling, then leukoplakia requiring biopsy, ultimately reaching non-healing ulceration indicating malignant transformation. This UV-driven condition affects older Caucasian males with 10:1 male-to-female ratio and more than doubles lip cancer risk.
• Clinical photography using smartphone cameras with flash activated and overhead lights turned off provides superior lesion documentation compared to intraoral cameras, and can be transmitted via secure methods for specialist consultation before biopsy procedures.

Perfect for: General dentists, dental hygienists, and oral surgery residents who need evidence-based protocols for leukoplakia recognition and management in clinical practice.

Don't let the 80% benign statistic create false confidence—discover why every white patch demands the same urgent attention.